title: [Three successful cases with CPT-11 + CDDP chemotherapy where S-1 failed to respond to recurrent gastric cancer].
abstract: We report three successful cases with irinotecan (CPT-11 60 mg/m2) + cisplatin (CDDP 30mg/m2) chemotherapy (once in 2 weeks) where S-1 failed to respond to recurrent gastric cancer. Case 1: A total gastrectomy and splenectomy were performed for a cardiac gastric cancer (T3, N2, H0, P0, CY0, por 1, Stage IIIB). An abdominal CT revealed paraortic lymph node metastases 4 months after the surgery. No reductions were noted after S-1 monotherapy. We next treated this patient with CPT-11 + CDDP. An abdominal CT revealed a CRin after 11 courses. Case 2: A total gastrectomy, splenectomy and cholecystectomy were performed for a cardiac gastric cancer (T3, N3, H0, P0, CY1, tub1, Stage IV). After the surgery, we treated this patient with S-1 mono-therapy. However, we finished this treatment for abdominal recurrence. We next treated this patient with CPT-11 + CDDP. An abdominal CT revealed a CR after 24 courses. Case 3: A distal gastrectomy and cholecystectomy were performed for a pyloric gastric cancer (T2, N1, H0, P0, CY0, tub 2, Stage II). An abdominal CT revealed paraortic lymph node metastases 10 months after the surgery. We treated this patient with S-1 + paclitaxel (PTX) chemotherapy. No reductions were noted after 2 courses. We next treated this patient with CPT-11 + CDDP. An abdominal CT revealed a CR after 8 courses.
authors.affiliation: Dept. of Surgery, Minoh City Hospital Gastrointestinal Research Center.
authors.forename: Rio
authors.initials: R
authors.lastname: Handa
authors.forename: Shouhei
authors.initials: S
authors.lastname: Iijima
authors.forename: Takashi
authors.initials: T
authors.lastname: Doi
authors.forename: Kazuteru
authors.initials: K
authors.lastname: Oshima
authors.forename: Minako
authors.initials: M
authors.lastname: Hoshi
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Makari
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Miyake
authors.forename: Satoshi
authors.initials: S
authors.lastname: Oshima
authors.forename: Takeshi
authors.initials: T
authors.lastname: Kato
authors.forename: Eiji
authors.initials: E
authors.lastname: Kurokawa
authors.forename: Nobuteru
authors.initials: N
authors.lastname: Kikkawa
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood; D002166:Camptothecin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002945:Cisplatin / Q000627:therapeutic use*; D004338:Drug Combinations; D005260:Female; D005500:Follow-Up Studies; D005743:Gastrectomy; D006801:Humans; D000077146:Irinotecan; D008207:Lymphatic Metastasis / Q000473:pathology; D008297:Male; D008875:Middle Aged; D010094:Oxonic Acid / Q000627:therapeutic use*; D012008:Recurrence; D016879:Salvage Therapy; D013274:Stomach Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology*; D005641:Tegafur / Q000627:therapeutic use*; D014057:Tomography, X-Ray Computed
chemical_list: D014408:Biomarkers, Tumor; D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D000077146:Irinotecan; D002945:Cisplatin; D002166:Camptothecin